NCT04865731 is a Phase 2 clinical trial of Dermaprazole in Cancer of the Head and Neck, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT04865731?

NCT04865731 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT04865731?

Interventions in NCT04865731: Dermaprazole, Aquaphor.

What condition does NCT04865731 study?

NCT04865731 studies Cancer of the Head and Neck.

Is NCT04865731 still recruiting?

NCT04865731 is currently completed. Last updated 6 August 2025.

Are results published for NCT04865731?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-08-06 · How we verify

NCT04865731

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer

Completed Phase 2 Results posted Last updated 6 August 2025

What this trial tests

Phase 2 trial testing Dermaprazole in Cancer of the Head and Neck in 6 participants. Completed in 18 June 2024.

Timeline

15 June 2022

Primary endpoint
18 June 2024

18 June 2024

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	6
Start date	15 June 2022
Primary completion	18 June 2024
Estimated completion	18 June 2024
Sites	1 location across United States

Drugs / interventions tested

Dermaprazole — full drug profile →
Aquaphor — full drug profile →

Conditions studied

Cancer of the Head and Neck — all drugs for Cancer of the Head and Neck →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

18 and older, any sex, with Cancer of the Head and Neck. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the study team seek to conduct a pilot clinical study to evaluate the safety and efficacy of a reformulated proton pump inhibitor (PPI) cream (Dermaprazole) in definitive head and neck cancer (HNC) patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation.
Dalwadi SM, Hunt A, Bonnen MD, Ghebre YT. · · 2023 · cited 8× · PMID 37274281 · DOI 10.3389/fonc.2023.1198284

Verify or expand the search:

Other recruiting trials for Cancer of the Head and Neck

Currently open trials in the same condition.

NCT04470024 — Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC · Phase 1 · recruiting
NCT02270814 — Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma · Phase 2 · active not recruiting

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04865731 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04865731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing